For people living with psoriatic disease, treatment innovation has advanced dramatically. Yet too many patients remain undiagnosed, untreated, or undertreated. The National Psoriasis Foundation […]
Connecting more patients with psoriasis to the care they need Read More »
BIO’s response to a request for information from the Drug Price Working Group explains why price setting won’t work. Improving patient access to new
Build patient access by strengthening innovation, BIO tells senators Read More »
2026 was a busy year on the state level. Whether it was the expected healthcare policy priorities or newer ones, there was plenty to
Mid-year review: State-level legislative action impacting biotech Read More »
When it comes to fighting cancer, time is of the essence. But far too often, utilization management (UM) practices such as prior authorization and
CancerCare project highlights barriers to patient access Read More »
Biotech innovation provides better-than-average salaries and pumps hundreds of billions of dollars into the U.S. economy annually—and the societal benefits of this innovation can
Studies show value of biotech IP for the economy and society Read More »
There was bipartisan support for the PASTEUR Act’s approach to addressing AMR and for NSCEB recommendations, both BIO priorities. A bipartisan Senate hearing sought
Senators seek solutions for AMR, maintaining US biotech leadership Read More »
Listening to people’s concerns about vaccines is key to helping them regain trust, according to experts promoting the need for life-saving immunizations. “We’ve all
BIO 2026: To restore trust in vaccines, listen to everyone’s concerns Read More »
“CAR-T cell therapies are remarkable drugs and are the gold standard for patients,” said Rachel Haurwitz, PhD, President & CEO of Caribou Biosciences. These
BIO 2026: Realizing the promise of CAR-T cell therapies Read More »
While the U.S. Food and Drug Administration (FDA) has faced significant change in recent years, industry leaders and agency officials alike say there are
BIO 2026: FDA leaders discuss restoring workforce, institutional knowledge Read More »
Industry leaders at BIO 2026 discussed the proposed PDUFA VIII next steps. After a year of discussion with the industry and 127 meetings with
BIO 2026: Industry PDUFA negotiators describe their agreement with FDA Read More »
